Examkin

Question

Difficulty: HardClinical Preventive Services and Screening

A 35-year-old man comes to the clinic to establish care. He has no significant past medical history and takes no medications. The patient reports a history of intravenous drug use in his early twenties but has been in recovery for the past 10 years. Physical examination is unremarkable. He is interested in undergoing appropriate health screenings. Arrange the following clinical steps in the correct chronological order for the screening, diagnosis, and management of the infectious disease most strongly associated with his risk factors.

  1. 1Perform Hepatitis C virus (HCV) antibody testing
  2. 2Perform quantitative HCV RNA polymerase chain reaction (PCR) testing
  3. 3Assess liver fibrosis stage and verify Hepatitis A and B immunity status
  4. 4Initiate treatment with an oral direct-acting antiviral (DAA) regimen
  5. 5Measure HCV RNA 12 weeks after therapy completion to confirm sustained virologic response (SVR)

Answer

The correct sequence is: HCV antibody testing, followed by HCV RNA testing, followed by assessment of liver fibrosis and Hepatitis A/B immunity, followed by initiation of DAA therapy, and finally measuring HCV RNA for SVR 12 weeks after completing therapy.
The sequence follows the evidence-based clinical cascade for Hepatitis C. The first step is the screening HCV antibody test. Because antibodies persist even after spontaneous clearance, a positive antibody test must always be followed by an HCV RNA PCR test to confirm active viremia. Once active chronic HCV is diagnosed, a critical pre-treatment evaluation is required. This involves staging the liver fibrosis (to determine regimen duration and necessity of future cancer screening) and checking Hepatitis A and B serologies (to vaccinate if necessary and prevent fatal HBV reactivation). After this workup is complete, patients are started on highly curative direct-acting antiviral (DAA) therapy. The final step in the sequence is confirming the cure, which is done by checking the HCV RNA level 12 weeks after finishing the medication to document a sustained virologic response (SVR).

Step-by-Step Solution

1
Identify the patient's screening needs based on his demographics and history.
The patient has a history of intravenous drug use, placing him at high risk for Hepatitis C. The first step in evaluation is the HCV antibody screening test.
Current USPSTF guidelines recommend routine HCV screening for all adults, starting with an antibody test to detect prior exposure.
2
Determine the necessary confirmatory test following a positive screening result.
Quantitative HCV RNA PCR testing must be ordered.
A positive antibody test only indicates exposure. Up to 25% of patients clear the virus spontaneously; RNA testing is required to confirm an active, ongoing infection.
3
Establish the required pre-treatment workup for confirmed chronic HCV.
Liver fibrosis must be staged, and immunity against Hepatitis A and B must be verified.
Fibrosis staging dictates the duration of therapy and the need for future liver cancer surveillance. Hepatitis B status must be known because treating HCV can trigger a dangerous reactivation of HBV.
4
Select the appropriate definitive intervention.
Initiate an oral direct-acting antiviral (DAA) regimen.
DAAs are the standard of care for treating chronic HCV, offering cure rates exceeding 95%.
5
Define the method for determining treatment success.
Measure HCV RNA 12 weeks post-treatment.
An undetectable viral load 12 weeks after stopping therapy is known as a sustained virologic response (SVR) and is considered a definitive cure.

Key Concept

The Hepatitis C care cascade involves initial antibody screening, confirmatory RNA testing, essential pre-treatment evaluation (including fibrosis staging and HBV/HAV immunity assessment), DAA therapy, and a test of cure (SVR12).
Rate this question

Topics

Clinical Preventive Services and Screening

More questions from this topic